CSF2 and amyotrophic lateral sclerosis: In the context of ALS–CSF–mediated disease, we show that E6 antibody slightly reduced NFκB activation in the brain of ALS–CSF–treated mice (Fig. 8e) without remarkably affecting microgliosis (Fig. 8b–c).